Opens in a new tab or window Upadacitinib combined with topical corticosteroids led to rapid and lasting relief from atopic dermatitis (AD) symptoms compared with placebo. Researchers also ...
来自MSN10 个月
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head StudyAbbVie said the study is the first head-to-head trial in atopic dermatitis assessing upadacitinib at a starting ... moderate-to-severe atopic dermatitis (AD) who had an inadequate response to ...
AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).
一些您可能无法访问的结果已被隐去。
显示无法访问的结果